PS-C13-8: IMPACT OF SACUBITRIL/VALSARTAN ON NT-PRO BNP LEVELS IN HYPERTENSIVE PATIENTS

Abstract

Background: Even a slight increase in plasmasNT-pro BNP levels is associated with an incremental cardiovascular events in a healthy cohort. Sacubitril/valsartan has recently been reimbursed in Japan for hypertension. Its impact on reducing plasma NT-pro BNP levels in hypertensive patients remains unknown. Methods: Patients who received 3-month sacubitril/valsartan administration for their hypertension were retrospectively included. Changes in plasma NT-pro BNP levels during 3-month sacubitril/valsartan therapy (on-treatment period) were compared with those during pre-treatment 3-month period (pre-treatment period). Results: A total of 33 hypertensive patients (73 [64, 77] years old and systolic blood pressure 138 [134, 149] mmHg on median) were included. During a pre-treatment period, systolic blood pressure tended to decrease (p = 0.091) whereas plasma NT-pro BNP levels remained unchanged (from 204 [132, 412] pg/mL to 207 [107, 386] pg/mL, p = 0.84). During on-treatment period, both systolic pressure and plasma NT-pro BNP levels decreased significantly (p < 0.001 and p = 0.001, respectively, from 207 [107, 386] pg/mL to 119 [64, 355] pg/mL in NT-pro BNP). The amount of changes in plasma NT-pro BNP levels during on-treatment period was significantly higher than those during pre-treatment period (-51 [-158, -17] mmHg versus -12 [-28, 33] mmHg, p = 0.001). Conclusions: Plasma NT-pro BNP levels decreased significantly following 3-month sacubitril/valsartan therapy. Its clinical implication requires further long-term studies.